Want to see ENLV full AI Analyst Report?
Top Page
Enlivex
(NASDAQ:ENLV)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.00
▼(-34.21% Downside)
Action:Upgraded
Date:08/29/26
The score is held down primarily by weak financial performance (no meaningful revenue, persistent operating losses, and ongoing negative operating/free cash flow). Technicals add further pressure with a pronounced downtrend and bearish momentum, despite oversold readings. Valuation looks superficially inexpensive on P/E, but that metric appears low-quality given the operating profile and lack of dividend support.
Positive Factors
FDA RMAT designation
RMAT designation validates encouraging early clinical evidence and provides enhanced FDA interaction with a potentially expedited pathway. This may improve development efficiency and regulatory clarity as Enlivex advances its 182-patient Phase IIb trial toward planned 2027 data.
Negative Factors
No commercial revenue and persistent losses
The absence of meaningful product revenue leaves Enlivex without a proven operating engine to fund research and development. Persistent operating losses mean future value depends on clinical success, regulatory approval, and eventual commercialization rather than established recurring sales.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA RMAT designation
RMAT designation validates encouraging early clinical evidence and provides enhanced FDA interaction with a potentially expedited pathway. This may improve development efficiency and regulatory clarity as Enlivex advances its 182-patient Phase IIb trial toward planned 2027 data.
Read all positive factors
Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.23M
Dividend YieldN/A
Average Volume (3M)414.35K
Price to Earnings (P/E)<0.1
Beta (1Y)0.65
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)405.30
Shares Outstanding17,485,462
10 Day Avg. Volume303,118
30 Day Avg. Volume414,352
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$80.00Price Target Upside5163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Enlivex Business Overview & Revenue Model
Company Description
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-bas...
How the Company Makes Money
As a clinical-stage biotechnology company, Enlivex does not have established recurring revenue from marketed products (null). Its business model is primarily funded through external financing and non-operating sources rather than product sales: (1...
Enlivex Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -332.00K | -545.00K | -835.00K | -777.00K | -546.00K |
| EBITDA | -14.67M | -14.47M | -28.22M | -25.02M | -18.74M |
| Net Income | 1.24B | -15.01M | -29.07M | -31.06M | -14.47M |
Balance Sheet | |||||
| Total Assets | 2.33B | 27.69M | 36.83M | 67.64M | 95.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.87M | 23.61M | 27.32M | 50.24M | 84.13M |
| Total Debt | 641.00K | 534.00K | 1.03M | 4.85M | 6.01M |
| Total Liabilities | 392.05M | 4.10M | 6.75M | 10.80M | 10.11M |
| Stockholders Equity | 1.93B | 23.59M | 30.08M | 56.84M | 85.04M |
Cash Flow | |||||
| Free Cash Flow | -10.48M | -13.11M | -23.76M | -32.08M | -19.17M |
| Operating Cash Flow | -10.42M | -13.01M | -23.52M | -23.95M | -17.54M |
| Investing Cash Flow | -1.32M | 9.06M | -25.97M | 62.52M | -38.41M |
| Financing Cash Flow | 10.38M | 6.45M | 360.00K | 150.00K | 60.98M |
Enlivex Technical Analysis
Negative
1.52
Price Trends
3.64
Negative
7.52
Negative
11.25
Negative
Market Momentum
-0.67
Negative
15.72
Positive
12.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Negative. The current price of 1.52 is above the 20-day moving average (MA) of 1.51, below the 50-day MA of 3.64, and below the 200-day MA of 11.25, indicating a bearish trend. The MACD of -0.67 indicates Negative momentum. The RSI at 15.72 is Positive, neither overbought nor oversold. The STOCH value of 12.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENLV.
Enlivex Risk Analysis
Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enlivex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $14.96M | -0.41 | -218.59% | ― | ― | 38.14% | |
46 Neutral | $20.08M | >-0.01 | -147.45% | ― | ― | ― | |
42 Neutral | $14.18M | -0.91 | -748.08% | ― | ― | ― | |
41 Neutral | $19.23M | <0.01 | 248.08% | ― | ― | ― |
* Healthcare Sector Average
ENLV
Enlivex
1.10
-14.50
-92.95%
DARE
Daré Bioscience
0.72
-1.41
-66.15%
AKTX
Akari Therapeutics
11.47
-22.53
-66.26%
PASG
Passage Bio
4.65
-2.27
-32.80%
Enlivex Corporate Events
Enlivex Restructures $19.2 Million Convertible Note With Lind, Easing Default Risk
Aug 11, 2026
On August 11, 2026, Enlivex Ltd. amended its senior secured convertible promissory note originally issued on March 23, 2026 to Lind Global Asset Management XIV LLC, adjusting key terms to address a prior default risk linked to the company’s ...
Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million
Jul 30, 2026
Enlivex Ltd., a longevity-focused biotech powered by a prediction markets treasury, reported a sharp increase in trading activity on the Rain protocol as part of its digital-asset strategy. The company’s dual focus on clinical-stage immunoth...
Enlivex to Brief Investors on Private Placement, Rain Treasury Strategy and Allocetra RMAT Milestone
Jul 29, 2026
On July 29, 2026, Enlivex announced that its management will host a live investor webinar on July 30, 2026, to discuss its recently disclosed private placement, capital allocation plans, and long-term treasury strategy anchored in the Rain protoco...
Enlivex Strikes $400 Million Private Placement Tied to RAIN Token Treasury Strategy
Jul 28, 2026
On July 27, 2026, Enlivex Ltd. signed a securities purchase agreement with the Rain Foundation, an existing institutional shareholder that manages the RAIN token ecosystem, for a $400 million private placement of ordinary shares or pre-funded warr...
Enlivex Secures $400 Million Premium-Priced Private Placement Backed by RAIN Tokens
Jul 28, 2026
On July 28, 2026, Enlivex announced it had entered a securities purchase agreement for a $400 million private placement of ordinary shares or equivalents with a single institutional investor, priced at $5.00 per share for subscriptions in U.S. dol...
Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share
Jul 20, 2026
On July 20, 2026, Enlivex reported an update on its RAIN token-based treasury portfolio, highlighting a net asset value per ordinary share of $66.16 as of July 18, 2026. The company disclosed that it held 79,550,593,122 RAIN tokens valued at appro...
Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis
Jul 13, 2026
On July 13, 2026, Enlivex announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Allocetra™, its clinical-stage immunotherapy, for treating age-related symptomatic knee osteoarthrit...
Enlivex Sets 1-for-15 Reverse Stock Split Ahead of July 9 Nasdaq Debut
Jul 7, 2026
On February 3, 2026, Enlivex shareholders approved a reverse split of the company’s ordinary shares within a broad ratio range and authorized the board to set the final terms. The board has now fixed the ratio at 1-for-15, with the split to ...
Enlivex’s Primary Treasury Asset RAIN Token set for Listing on Major Exchange Gate
Jun 24, 2026
Enlivex Ltd., a longevity-focused biotech company integrating a prediction markets-based digital treasury, reported that its primary treasury asset, the RAIN token, is a governance and utility token for a decentralized predictions and options prot...
Enlivex Values RAIN Token Treasury at $1.14 Billion as of June 20, 2026
Jun 22, 2026
On June 22, 2026, Enlivex reported that as of June 20 it held 79,568,550,005 RAIN tokens valued at approximately $1.14 billion, underscoring the growing weight of digital assets in its balance sheet. The company said its treasury net asset value p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.